Embed Size (px)
Citation preview
nt<:t lill'IJ.--enn. open-lilbel ;::',dy t' 1<.1 7 '" J.:alp
SOLARAZE® Gef starts strong
esults from a phase 4, multicenter study (N:::76)1
Proven e
• Well-tole High rate
with simila
Only 0 A 100-g tube 0
One tube can
\ -75% of~
-- 84% ofpa,
Please see Sel Please see att!
Mark()~cd by
I, harn'
Ad,."iSi<'lflOf
WWW"
wwws...
SOLARAlE is a regislered Ira\. @2QO--8.PhalillaDerm Melville,c
.... 10 1 a.4o 1/1 ... c: 8CIl 0 6.1.cE '-1/1 6::J'!! c: 4c:~ cg ... <II III 2:E
o Baseline 30 days 60 days
Number of days
10~ 1 pYlenl:s . ·18 )"'<11;. ,f ao," ,'tII .an aoe ,f til" idf') ,,,,M,S c::r 'e, thu . -y e, (l k,k '1Il!Jlhty wei" "." oll~,j f('l llT'~I~"t r" '1ICojl ?U d
I, .)Jolf J PI~"::L (V, ooer. ~L··I 0'~!.t...'"S"1 u.:nt ,-,' the :remrnellt ,'If 11 11.. _ ~ ',..." ·tl J Jh..,.hl~t 1ir.::1 'nn.cal z:,.?! ,::i:')l,ycL:"" ilJl
Significant improvement in the first 30 days of a phase 4, multicenter study
• A steady decrease in lesions was observed at Days 30, 60, and 90
Proven efficacy, with continuous improvemen~ during the course of treatment when used as prescribed
't3
QI ::J Q.
."S"}o
100% clearance
'~-"-ntl
CLNS
720/0
~75% clearance100% clearance
58"}o
ith continuous i
TLNS
TINS =,.,""'~ L~bl rlllln(xr SCClf~, cLNS '" (umuIJtr..,~ hx,i:,;O, rlurnt'tt S<w:
~75% clearance
Investigator Global Improvement Index showed that 84% of lesions were significantly or comDletely improved by Day 120 (follow-up 30 days posttreatment)
. 100 ~ ~ CII 80
'1li... 60 CII U 40c: l!! l'lI 20 CII U 0
QI
j n
Please see selected Safety Infonnation on page 6 and the back cover. Please see attached full Prescribins Information.
-
----*- Mean number of cumulative lesions
onstrated efficacy across muttiple targeted body areas2/3®Gel
Results from a phase 3 clinical trial evaluating SOLARAZE® Gel on face, forehead, scalp, hands, and forearmco90 days of treatment, 3Q, days posttreatment (N=120)
so
Only O· A 100-g
One tub~ II 7 III ~ Mean number of target lesions ~ 6 0
"iii 5.!SOLARAl~ 40 -...Selected Q) 3 .D
SUN AVOI E 2
c:DiCiOfena1 ~
c:polyps, 0 Cll
Q) 0 ulcerati9' :IE Baseline Visit 3 Visit 4 Visit 5 30 days o com . posttreatment
P<!'. Pleas Pleas
ClL of patients had complete clearance in all targeted areas
• 47% of patients had complete clearance of cumulative leslons (including new and subclinical lesIons
't'''1
SOLARAZE is a,(\ 1&)2008 PllarmaOe\
as dy of AK of th ace nd seal (N=30)
• 89% of patients achieved complete AK clearance, and 93% of patients had a 66% rate of clearance
7% of patients achieved a Global Improvement Score of moderately improved or better
9\Ja stud o ofth Ii (N
100% of patients achieved complete or significant improvement by 1 month
posttreatment (Day 120)*$
100
80 iz - -----,. r~1/1 60 C ;: ~
I 1Il Q. l I~J
IT~f 'II III 'I 1--,
30 days 60 days 90 days 120 days (30 days po.n",atmenl)
Number of days
&l ~
DJ II' tQ ~ ...,
Q. I -0 r-: "0
n
Please see Selected Safety Information on page 6 and the back cover. Please see attached full Prescribing Information.
SO·I""I.n._, ® Gel-an impress' tol bili'tY profil.,.2,4,!J
Most related adverse events were mild to moderate in severity2
Significantly less incidences of erythema, scaling, oozing/crusting, and edema than fluorouracil 5% cream4
• A favorable tolerability profile4,5
A low incidence of irritation4
A high rate of patient satisfaction4,5
• A unique safety profile4,5
In llmon adVtJrSB rsadiol1S involved the skm illld Included contact dermatitis lash, drv skin ana r.x'foliatmn, ions wertf milli to lllo00-ate in sevGritv< and resolved uoon (jjscontinlJatlon of thtlrapy
·gh rate of complian • The majority of patients were compliant w,ith the SOLARAZE® Gel regimen
5% of patients reported missing 6 or less applications at Day 90 (180 applications)
A high rate of patient satisfactionj!,5
79% of patients reported being either very satisfied or completely satisfied with SOLARAZE® Gel treatment4
~
~ t"
... QI ::r
Please see Sekcted Safety Information on page 6 and the back cover. Please see attached full Prtsaibing Information.
01
Proven efficacy-90% mean decrease in target lesions at Day 120 (follow-up 30 days posttreatment)l
Well-tolerated therapy--·most related adverse events were mild to moderate in severity2
High rate of patient compliance and satisfaction
- 75% of patients reported missing 6 or less applications at Day 90 (180 applications)l
84% of patients strongly agreed they would recommend SOLARAZE® Gel to others with similar lip lesions5
Only A 100-g tube of SOLARAZE® Gel-·-·-only one co-pay
One tube can complete a full course of therapy
Please see Selected Safety Information on page 6 and the back cover. Please see attached full Prescribing Information.
\.J t: __ ~ ::l .2.~~
a. ~'6Sl"i_ 0 ~
o C/lfI'J.2' c: u 0'1 Ja: ~ ~.§ .~fZ §.2 ~':I....--.J u.2"'·lo - u '._z ~i5o':lW (V) <Ii fij :-s
~ -~ (/] .c ... t!J Z ~.8a;.~® 0 ~E Q;'~ ~
OJ wW ~ ::l -~::J '63:.0 000.2N~~ ell = 0 I." CJ u ~ (11. .1.:c;.J 0 ~2:'ou« E ...J 2 :E ~ t0:.2 0 Z .g g-s0.- '" w ..,«;§~ i=~.8Eg
I U a: .---I co w ~ Q, '" .~ ij
a:i;jgj~foO .N 0 .... "1::.0.Q a: U)~O:JC' rn.~ 0 UJO ~~85li!Ll.
r·J~tw<.IOO g
Marku!ej by
PharmaDerm l' CI .... 'SIUI' .. )( NyCOfU..<i UC; I ,-ww r;lwonaderm COOl
V"V",v"Y w1ara/c.colll
SOLARAZ.E is aregistered trademark of PharrnaOerm. adivision 01 Nycomed US Inc (c)2008 PharrnaDerm. Melville. NY 1174"(. All rights reserved. 98NSG010209
